Search the Newsreel

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Análise e Previsão das Ações da Pfizer Inc (PFE)

Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP significantly reduced its stake in Pfizer Inc. by 37.7% in the second quarter of 2026, selling over 510,000 shares. Despite this, Pfizer reported strong Q2 earnings, exceeding analyst expectations for both EPS and revenue, and raised the low end of …

Pfizer Inc (PFE) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

How Pfizer Thinks About AI

Albert Bourla, CEO of Pfizer, outlines the company's ambition to be the most AI-forward in the pharmaceutical industry. He details three key strategies: structuring 177 years of data, federating AI across the organization to empower employees, and investing in AI fluency for all colleagues. …

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

Company Logo Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding …

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …

Earnings To Watch: OppFi Inc (OPFI) Q2 2026 -- GF Value Sees 74% Downside

Warum die Pfizer-Aktie (PFE) trotz eines Nettoverlusts im zweiten Quartal um 5,2 % gestiegen ist, nachdem das Unternehmen seine Prognose für 2026 angehoben hat

Why Pfizer (PFE) Is Up 5.2% After Raising 2026 Guidance Despite a Q2 Net Loss

Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Novavax Inc (NASDAQ:NVAX) has secured licensing or material transfer agreements with 4 of the TOP10 …

Pfizer Inc Earnings Call Signals Cautious Optimism

Pfizer Inc.'s Q2 earnings call revealed cautious optimism, with core revenues and adjusted EPS surpassing expectations, leading to raised full-year revenue guidance. The company demonstrated strong performance in oncology and neuroscience, alongside significant R&D activity, despite setbacks from a clinical trial miss, weaker COVID …

Pfizer shares rise after strong Q2 earnings des...

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)

This article provides analyst ratings and price targets for three healthcare companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE), and Allogene Therapeutics (ALLO). Citi analyst Geoff Meacham maintained a Hold rating on Pfizer, while Citi analyst Yigal Nochomovitz maintained a Buy rating on Ultragenyx Pharmaceutical. William …

OppFi Inc. Share Price Live Today – NYSE:OPFI Stock Price, Chart, News, History

Pfizer (PFE) Stock Trades At A Premium Despite Its 27% Five Year Fall

Pfizer’s Q2 Earnings Beat by Double Digits. A $4.3 Billion Writedown Stole the Headline.

Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year …

Pfizer Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:PFE) 2026-08-04

This article provides access to the slide deck published by Pfizer Inc. in conjunction with their Q2 2026 earnings call. The report highlights that Pfizer's EPS of $0.77 beat expectations by $0.09, and revenue of $15.03 billion, up 2.60% year-over-year, beat by $645.82 million.

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

This article first appeared on GuruFocus. Pfizer (NYSE:PFE), the pharmaceutical giant behind some of the world's biggest blockbuster drugs, edged about 0.5% lower in Tuesday's early trading despite delivering another earnings beat and raising its revenue outlook. The market appeared unconvinced that better quarterly …

Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts

Pfizer Inc. PFE used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity. Management raised the midpoint of full-year revenue guidance, expanded savings targets and reinforced the dividend. The call …

Company News for Aug 5, 2026

Allison Transmission Holdings Inc.'s (ALSN) shares surged 5.4% after reporting second-quarter 2026 adjusted earnings of $2.73 per share, surpassing the Zacks Consensus Estimate of $2.60 per share. Shares of The Clorox Co. (CLX) climbed 6.5% after posting fourth-quarter fiscal 2026 adjusted earnings of $1.66 …

Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading

Pfizer (PFE) Stock Faces Pipeline Doubts After Higher Revenue Outlook

Pfizer Earnings Reveal New Engine Beyond Covid

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) delivered stronger-than-expected second-quarter results as Specialty Care and newer acquired medicines offset continued weakness across Primary Care, reinforcing the company's transition away from pandemic-era products. The split matters because Pfizer's recovery increasingly depends on specialty drugs …

Pfizer beats earnings estimates, targets US$2.5 billion in additional cost cuts

Pfizer reported strong Q2 results, exceeding earnings estimates, driven by demand for Eliquis and acquired drugs. The company announced plans for an additional $2.5 billion in cost cuts, aiming for a total of $9.7 billion in net savings by 2029 to offset declining COVID-related …

Pfizer Earnings: Strong Growth for Newer Drugs Counters Covid Declines

Pfizer reported 3% revenue growth in the second quarter and maintained its adjusted diluted EPS guidance for 2026, leading to a 2% rise in shares. The company's newer drugs like Nurtec, Lorbrena, and Padcev are driving growth, offsetting reduced demand for COVID-19 products. Morningstar …

Pfizer Inc. Passt Gewinnprognose für 2026 an

PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut

Pfizer PFEreported second-quarter 2026 adjusted earnings per share of 77 cents, which beat the Zacks Consensus Estimate of 68 cents per share. Earnings were flat year over year. Revenues came in at $15.03 billion, up 3% from the year-ago quarter on a reported basis …

Pfizer's Recovery Story Is Starting to Look More Durable

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials), the pharmaceutical firm, said its second-quarter earnings topped Wall Street estimates and boosted its annual revenue guidance, as growth in its non-COVID portfolio compensated for a steep drop in Paxlovid sales.Adjusted earnings of 77 …

Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout Looms

Pfizer beat second-quarter expectations Tuesday, offsetting a continued steep decline for its Covid products. But Pfizer stock fell. Continue Reading

Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics

Pfizer (PFE) reported $15.03 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 2.6%. EPS of $0.77 for the same period compares to $0.78 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $14.45 billion, …

NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before …

Is Pfizer (PFE) A Bargain Following Its Earnings Beat And 2026 Guidance Lift?

Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue

Pfizer's (NYSE:PFE) Q2 CY2026: Beats On Revenue Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 2.6% year on year to $15.03 billion. The company expects the full year's revenue to be around $61.5 billion, …

Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as …